Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-C11: Pembrolizumab and Chemotherapy in Newly Diagnosed Classical Hodgkin Lymphoma
NCT05008224Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Merck & Co. Primary endpoint: Complete Response Rate at the End of Study Intervention up to 24 months. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05008224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008224.